In a study published in Virologica Sinica , a team of researchers established a chikungunya virus (CHIKV) replicon particle (VRP)-based screening platform and identified three candidate antiviral compounds that interfere with different stages of the viral life cycle. The study provides a framework for the identification and characterization of anti-CHIKV compound and highlights the potential of combining biosafe screening approaches with mechanistic analyses to explore new antiviral strategies against emerging viral pathogens.
Chikungunya virus (CHIKV) is a re-emerging mosquito-borne alphavirus that can cause severe joint pain and prolonged inflammatory symptoms. Despite its increasing global spread, including a large outbreak in Foshan, Guangdong Province, China, in 2025, no specific antiviral therapy is currently available.
“We established a biosafe CHIKV VRP-based screening platform using the predominant strain from the Foshan outbreak and applied it to identify potential antiviral compounds,” shares senior and co-corresponding author Rong Zhang, a professor in School of Basic Medical Sciences at Fudan University. “High-throughput screening of a small-molecule library led to the identification of three candidates: MDL-12330A, bazedoxifene acetate, and anidulafungin.”
To investigate how these compounds affect CHIKV infection, the researchers combined multiple complementary experimental systems to examine different stages of the viral life cycle, including viral entry, replication-associated processes, and viral particle production. “We found that distinct antiviral profiles among the three compounds, suggesting that CHIKV infection can be inhibited through different mechanisms involving both viral life cycle and host cellular functions,” says Zhang.
“By integrating a VRP-based screening platform with functional evaluation systems, we were able to identify candidate compounds with different antiviral profiles and better understand how host–virus interactions influence CHIKV infection,” says lead author Yang Gao.
###
Contact the author:
Rong Zhang, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China, rong_zhang@fudan.edu.cn.
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 200 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Virologica Sinica
Experimental study
Cells
Identification and characterization of anti-chikungunya virus compounds using a biosafe toolkit
The authors declare no competing interests.